PMOS Renames PCOS to Reflect Metabolic-Endocrine Reality for 170 Million Women
Global experts and patient groups have renamed Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its hormonal and metabolic features and reduce stigma; the shift, supported by more than 50 organizations and published in The Lancet after 14 years of work, aims to improve diagnosis and care for about 170 million women worldwide, with full implementation in the 2028 international guideline update and new evidence showing no increase in abnormal ovarian cysts.